NASDAQ$NKGN
Nkgen Biotech Inc · Q3 2024 earnings
Q3 2024 earnings · · After market close · Investor relations
Briefing
NKGen Biotech reported Q3 2024 net income of $6.6M.
For Q3 2024, NKGen Biotech reported net income was $6.6M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net income $6.6M.
- MD&A highlights operating priorities, liquidity, and sector risks.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Nkgen Biotech · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, cash runway, and R&D spend.
Tailwinds
- Pipeline progress and partnership optionality.
- Balance-sheet flexibility where noted.
Headwinds
- Operating losses until commercialization.
- Trial, regulatory, and financing risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2024
+6.0%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+2.7%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+57.1%
Q1 2024
Best reaction
-16.9%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +0.0% | +0.0% | |
| Q1 2025 | +0.0% | +0.0% | +0.0% | |
| Q2 2025 | +0.0% | +0.0% | +85.0% | |
| Q4 2024 | +21.4% | +0.0% | -5.0% | |
| Q3 2024 | +36.1% | +4.7% | -5.8% | |
| Q2 2024 | -0.8% | -37.1% | -64.1% | |
| Q1 2024 | +57.1% | +26.8% | +6.3% | |
| Q4 2023 | -16.9% | -10.8% | -8.9% | |
| Q3 2023 | +5.1% | +2.6% | +37.9% | |
| Q2 2023 | +0.3% | +0.8% | -2.9% | |
| Q1 2023 | +0.3% | -0.3% | +0.0% | |
| Q4 2022 | +0.3% | -0.3% | +0.0% | |
| Q3 2022 | -0.3% | +0.3% | +0.5% | |
| Q2 2022 | +0.0% | +0.0% | -0.1% | |
| Q1 2022 | +0.0% | +0.3% | +0.7% | |
| Q4 2021 | +0.0% | +0.3% | +0.7% | |
| Q3 2021 | +0.0% | +0.2% | +1.0% | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro